NEW YORK (GenomeWeb) – Angsana Molecular & Diagnostics has announced a partnership with Ignyta on screening for a cancer therapy clinical trial being conducted in Asia.

Under the terms of the agreement, Angsana will provide cancer screening using its RNA-based cancer panel to detect TRK, ROS1, and ALK fusions in patients participating in the STARTRK-2 Phase 2 basket trial for entrectinib, a tyrosine kinase inhibitor. The firm will support the trial from its CAP-accredited labs in Singapore and Hong Kong.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.

Sponsored by

This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Sponsored by
Agilent Technologies

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.